¿Deben indicarse trombolíticos a los ancianos mayores de 75 años con síndrome coronario agudo y supradesnivel del ST? (Agonista)
Trongé, Jorge.
Rev. argent. cardiol
; 72(1): 52-55, ene.-feb. 2004. tab
Artículo en Español | BINACIS | ID: bin-3450
Documentos relacionados
Effects of a New Antithrombotic Drug GRS, a Soluble Guanylate Cyclase Stimulator, on Endothelial Dysfunction in Rats with Myocardial Infarction.
Protecting patients during a shortage of thrombolytic agents.
Long term antithrombotic threapy after myocardial infarction: why, to whom and which one?
Acute Myocardial Infarction after Intravenous Thrombolysis for Acute Ischemic Stroke: Case Series and Systematic Review.
Pharmaco-invasive Therapy with Fibrinolytic Agents: A Potent Lifesaving Reperfusion Strategy in STEMI Patients in Metro/Tier-I Cities in India.
The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy.
Effects of grafting on chemical constituents, toxicological properties, antithrombotic activity, and myocardial infarction protection of styrax secreted from the trunk of Liquidambar orientalis Mill.
Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?
Antithrombotic Activity of the Antiplatelet Agent Angipur on the Model of Arterial Thrombosis in Rats with Isoproterenol-Induced Myocardial Infarction.
[Pharmaco-invasive approach in the management of acute myocardial infarction. Analysis of 144 cases].